Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-Label, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults (Aged 18-31 Years) With Complex Lymphatic Malformations

Next Previous
Trial Profile

A Phase 1b, Open-Label, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults (Aged 18-31 Years) With Complex Lymphatic Malformations

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 10 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AVTX 006 (Primary)
  • Indications Lymphatic disorders
  • Focus Adverse reactions; Proof of concept
  • Sponsors Avalo Therapeutics

Most Recent Events

  • 07 Mar 2022 Planned initiation date changed from 1 Aug 2021 to 3 Sep 2021.
  • 07 Mar 2022 Status changed from recruiting to withdrawn prior to enrolment.
  • 06 Jan 2022 According to an Avalo Therapeutics media release, the company anticipates initial data from this clinical trial in the mid of 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top